Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today ...
Seven years ago, Johns Hopkins researchers and their collaborators announced they had found the X cell, a novel immune cell ...
Long-term research funding support from the NIH might one day play a key role in reversing the progression of Type 1 diabetes ...
Caspian Therapeutics was launched with $50 million to progress KO-7246 through IND-enabling development and early clinical evaluation in patients with diabetes. Menin inhibition is positioned as ...
Novel laser-fabricated plasmonic chip combines 185 nm Raman resolution and deep learning to identify and sort cancer ...
Uppsala, September 9, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell thera ...
Seven years ago, Johns Hopkins researchers and their collaborators announced they had found the X cell, a novel immune cell ...
Independent studies conducted at Northwestern University and Mayo Clinic demonstrate synergistic activity of elraglusib in combination with ...
New research suggests a structured program that combines regular exercise with a brain-friendly diet may help improve memory ...
Kale and spinach both have nutrients with anti-inflammatory and antioxidative properties. Comparing kale versus spinach, is ...
Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results